Alison Stopeck, MD
Hematology & Oncology · Tucson, AZNPI 1144392291
Payments from drug & device makers
Across 211 payments — averaging $6177.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$509K
- Biontech SE$201K
- Merck$120K
- Pfizer$116K
- Seagen Inc.$110K
- AstraZeneca$60K
- plus $186K from 18 others
Across 17 payments — averaging $3085.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$34K
- Astrazeneca UK Limited$9K
- Amgen$6K
- G1 Therapeutics, Inc.$4K
- Boehringer Ingelheim International GmbH$200
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 21 | $509,042 |
| Biontech SE | 42 | $201,424 |
| Merck | 4 | $119,908 |
| Pfizer | 21 | $116,182 |
| Seagen Inc. | 24 | $110,397 |
| AstraZeneca | 14 | $60,320 |
| Genentech, Inc. | 18 | $55,530 |
| Radius Health, Inc. | 4 | $53,363 |
| F. Hoffmann-la Roche AG | 1 | $19,300 |
| Stemline Therapeutics Inc. | 22 | $18,861 |
| Beigene, Ltd. | 3 | $10,725 |
| Hexal AG | 2 | $7,479 |
| Boehringer Ingelheim International GmbH | 6 | $5,800 |
| Sandoz | 2 | $5,489 |
| Gilead | 6 | $4,226 |
| Athenex Pharmaceutical Division, LLC | 6 | $2,522 |
| Astrazeneca UK Limited | 1 | $2,275 |
| Daiichi Sankyo Inc. | 6 | $342 |
| Caris MPI, Inc. | 1 | $132 |
| Novartis | 3 | $103 |
| Genentech USA, Inc. | 1 | $30 |
| Tersera Therapeutics LLC | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $15 |
How this compares
$1,303,507 in reported general payments places this provider in the 80th percentile of 261 hematology & oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Tucson
- Sudhir MandaTucson$10M
- Rachna ShroffTucson$3M
- Aaron ScottTucson$2.6M
- Manuel Modiano RevahTucson$1.7M
- Rachel SwartTucson$1.6M
- Aisha AhmedTucson$1.6M
- Faiz AnwerTucson$1.3M
- Ahmed AbdelazizTucson$962K
- Ricklie JulianTucson$840K
- Richard RosenbergTucson$778K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.